AlphaRose Therapeutics
About this raise
AlphaRose Therapeutics, with a valuation of $12.09 million, is raising funds on StartEngine. The company is pioneering personalized medicine for children with rare genetic diseases. AlphaRose Therapeutics rapidly develops and commercializes treatments for children with generic diseases and is focused on neurodevelopmental conditions using its antisense oligonucleotide technology. The company has already developed a proprietary treatment for genetic mutations in HNRNPH2, Rosiphersen, and has a developing pipeline identified by its AI program Argus. Casey McPherson founded AlphaRose Therapeutics in October 2023. The current crowdfunding campaign has a minimum target of $123,998.85 and a maximum target of $1.23 million. The campaign proceeds will be used for research and development, company employment, and working capital.
Investment Overview
Committed $1,138,327 :
Deal Terms
Company & Team
Company
- Year Founded
- 2023
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $1,070,000
- VC Backed?
- No
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
04/30/2025 | StartEngine | $12,089,089 | $1,138,327 | Equity - Common | Active | RegCF |